NAD+ is the cell's central redox coenzyme and the substrate sirtuins and PARPs consume. A research overview of its mechanism, the bioavailability problem, precursor strategies, and what the human data actually shows.
Start with the label correction, because it shapes everything downstream: NAD+ is not a peptide. It is nicotinamide adenine dinucleotide — a dinucleotide coenzyme built from two nucleotides joined through their phosphate groups, present in every living cell. It gets shelved alongside research peptides in catalogs (including this one) because the research community that buys peptides is the same community studying cellular aging, and NAD+ sits at the center of that conversation. But chemically it shares nothing with a sequence of amino acids. Knowing what it actually is — a coenzyme, not a signaling peptide — is the first step to reading the literature correctly.
NAD+ is one of the most studied molecules in biology, with a research history stretching back to its discovery by Arthur Harden and William Young in 1906. What changed in the last fifteen years is not the basic biochemistry — that has been settled for decades — but the discovery that NAD+ is consumed, not merely recycled, by a family of enzymes tied to aging and DNA repair. That single insight reframed a textbook coenzyme as a candidate longevity target.
NAD+ does two distinct jobs, and conflating them is the most common source of confusion.
The first is redox chemistry. NAD+ and its reduced form NADH shuttle electrons through the core energy pathways — glycolysis, the citric acid cycle, and oxidative phosphorylation. Here NAD+ is a true catalyst: it is reduced to NADH and then re-oxidized back to NAD+, cycling indefinitely without being used up. This is the role every biochemistry textbook describes.
The second job is the one driving current research interest: NAD+ is a substrate that gets degraded by three classes of enzymes. The sirtuins (SIRT1–7) cleave NAD+ to deacetylate target proteins, linking NAD+ availability to gene regulation, mitochondrial biogenesis, and stress resistance. The PARPs consume NAD+ during DNA-damage repair. And CD38, an enzyme that rises with age and inflammation, is a major NAD+ sink. Because these enzymes break NAD+ apart rather than recycle it, the cell has to continuously resynthesize it — and the supply chain for that resynthesis is what declines with age.
That decline is the mechanistic anchor: across multiple tissues, NAD+ levels fall with age while CD38-driven consumption rises. The hypothesis under investigation is whether restoring NAD+ toward youthful levels restores any of the downstream functions — sirtuin activity, mitochondrial output, DNA-repair capacity — that decline alongside it.
Here is where research design gets hard, and where most of the marketing gets loose. NAD+ is a large, charged molecule. It does not cross cell membranes efficiently in its intact form. Swallow NAD+ and much of it is degraded in the gut before it reaches circulation; the body largely has to break it down and rebuild it inside the cell through the salvage pathway, where the rate-limiting enzyme NAMPT converts nicotinamide back into the NAD+ precursor pool.
This is exactly why most of the serious human work has focused not on NAD+ itself but on its precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These smaller molecules feed the salvage pathway and reliably raise blood NAD+ levels in human trials. The precursor strategy is associated with researchers like Charles Brenner (NR), Shin-ichiro Imai (NMN and NAMPT biology), and David Sinclair's group (sirtuin and NMN work). When people refer loosely to "NAD+ supplementation," they almost always mean precursor supplementation — a distinction worth keeping straight when comparing protocols.
Direct NAD+ administration sidesteps oral degradation by using parenteral routes — intravenous infusion in clinic settings, and subcutaneous administration in research protocols. This is the form most relevant to readers handling a lyophilized research compound. The trade-off is that parenteral NAD+ still faces the membrane-permeability question at the tissue level, and rapid IV infusion is associated with well-documented transient discomfort (flushing, chest tightness, nausea) that paces the infusion rate in clinical use.
There is no single clean half-life figure to quote, because NAD+ pharmacokinetics depend heavily on route and on the body's aggressive recycling of its breakdown products. Oral NAD+ is poorly bioavailable. Oral precursors (NR, NMN) raise circulating NAD+ measurably, typically peaking within hours and sustaining an elevation that the salvage pathway maintains. Parenteral NAD+ produces a sharp rise followed by rapid distribution and metabolism, with the molecule's constituent parts re-entering the salvage pool rather than being cleanly cleared.
For research handling, NAD+ is supplied lyophilized and reconstituted before subcutaneous use — the same workflow as any peptide in the catalog, covered in reconstitution basics and the dosing-math guide. The compound is light- and moisture-sensitive and follows standard cold-chain storage.
This is the part to read soberly. Precursor trials have consistently demonstrated one thing: oral NR and NMN raise blood NAD+ levels in humans, and do so with a clean safety profile in the doses studied. That endpoint — "it raises NAD+" — is well replicated.
The harder endpoint — "raising NAD+ produces meaningful clinical benefit" — is where the evidence thins out. Human trials of NAD+ precursors have reported mixed and generally modest results on metabolic markers, physical function, and inflammatory measures, with several rigorous trials showing NAD+ levels rise without corresponding changes in the downstream outcomes researchers hoped to move. The gap between "the biomarker moved" and "the phenotype improved" is the central open question of the entire field.
Direct IV NAD+ therapy, widely marketed in wellness and addiction-recovery settings, rests on a much thinner evidence base than the precursor trials — largely anecdotal and small-scale, without the controlled replication that precursor studies have accumulated. A researcher reading this literature should weight the precursor data heavily and treat strong claims about IV NAD+ outcomes as hypotheses, not findings.
NAD+ is most often discussed as part of a multi-mechanism longevity stack, alongside compounds like MOTS-c and Epithalon. The design logic is that these molecules hit different nodes of aging — NAD+ targets the redox/sirtuin axis, MOTS-c the AMPK/mitochondrial axis, Epithalon the telomerase/circadian axis — so a combination might produce a broader effect than any single intervention. The empirical evidence for synergy between them does not yet exist; the rationale is mechanistic, not demonstrated. Building and testing such a stack systematically is exactly what the four-phase research cycle is for.
NAD+ is the catalog's entry point into redox-axis longevity research. Readers should carry three things away from this overview: it is a coenzyme rather than a peptide, the precursor route (NR/NMN) is where the strongest human bioavailability data lives, and the distance between raising NAD+ and improving any clinical outcome remains the field's unresolved question. That honesty is the point — the biology is real and central, and the therapeutic claims are still being tested.
Is NAD+ actually a peptide? No. NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, not a chain of amino acids. It is grouped with research peptides in catalogs because the same research community studies both in the context of cellular aging, but chemically it is a different class of molecule entirely.
What is the difference between NAD+, NMN, and NR? NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors — smaller molecules that the body converts into NAD+ through the salvage pathway. Most human trials use precursors because they are far more bioavailable when taken orally than NAD+ itself.
Why is NAD+ given by injection or IV instead of orally? NAD+ is a large, charged molecule that is poorly absorbed orally and largely degraded in the gut. Parenteral routes (IV or subcutaneous) bypass that degradation. This is also why most oral supplementation strategies use precursors like NR or NMN rather than NAD+ directly.
Does raising NAD+ levels actually slow aging? The honest answer is unresolved. Trials reliably show that NAD+ precursors raise blood NAD+ levels with a good safety profile, but evidence that this produces meaningful clinical benefit — on metabolism, physical function, or longevity — is mixed and preliminary. The gap between moving the biomarker and improving the outcome is the field's central open question.
How does NAD+ relate to sirtuins? Sirtuins (SIRT1–7) are enzymes that consume NAD+ as a substrate to regulate gene expression, mitochondrial function, and stress resistance. Because they break NAD+ apart rather than recycle it, sirtuin activity depends on a continuous NAD+ supply — which is part of why declining NAD+ with age is hypothesized to matter.
